Screening and preparation method and application for antibody medicament for malignant lymphoma and autoimmune diseases

Abstract

The invention relates to screening and a preparation method and application for an antibody medicament for malignant lymphoma and autoimmune diseases, and discloses a lymphoma specificity humanized antibody for resisting HLA-DR10, a person and whole person monoclonal antibodies and segments thereof, and a radioactive isotope labeling antibody thereof including a heavy chain and a light chain, wherein the heavy chain contains a constant region, a heavy chain variable region amino acid sequence is SEQID NO:1, the light chain contains a constant region, a light chain variable region amino acid sequence is SEQID NO:2, and the heavy chain is connected with the light chain through a disulfide bond. The invention obtains NSO and CHO engineering cell strains of stable high-level expression lymphoma specificity humanized, person and the whole person monoclonal antibodies (chlym-1 antibody) for resisting the HLA-DR10, adopts a serum-free high density culture technique so that the expression of the chlym-1 is more than 500 milligrams per liter, and discloses application of the monoclonal antibodies in treating the malignant lymphoma and the autoimmune diseases.

Description

technical field [0001] The invention relates to the screening, preparation and application of monoclonal antibody drugs. Background technique [0002] Malignant lymphoma (ML) is a malignant tumor originating from lymph nodes and extralymphatic lymphoid tissues. ML can be divided into two categories: Hodgkin's lymphoma (HD) and non-Hodgkin's lymphoma (NHL). In my country, NHL patients account for 85-90% of new cases of malignant lymphoma. In NHL, the incidence of low-grade lymphoma with good prognosis is low in my country, accounting for about 5% of NHL; while the incidence of high-grade lymphoma with poor prognosis is relatively high, accounting for about 30% of NHL. The survey shows that with the passage of time and the development of social economy, malignant lymphoma presents an increasing trend, in which HD is relatively stable, while the morbidity and mortality of NHL are increasing. The etiology and pathogenesis of non-Hodgkin's lymphoma have not yet been determined,...

AI Technical Summary

Problems solved by technology

At present, chemotherapy is the main treatment for NHL, but the short-term side effects of chemotherapy are obvious, and the effect on relapsed patients is not sure, and the effect of general chemotherapy combination scheme is not good; Diagnosis, very easy to relapse, need to be combined with chemotherapy; bone marrow transplantation is difficult to carry out due to reasons such as difficulty in matching, rejection, and high price

However, due to the large dosage and complicated manufacturing process, the price remains high, and the injection interval is relatively short, which brings a lot of inconvenience to patients.